5,7-Difluoro-2,3-dihydro-1H-inden-1-amine | 173998-72-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5,7-Difluoro-2,3-dihydro-1H-inden-1-amine
• CAS: 173998-72-6
• 化学式: C₉H₉F₂N
• mdl: MFCD07373929
• 分子量: 169.17
• InChiKey: WFNMSZYZLUAEER-UHFFFAOYSA-N

物化性质

• 沸点：
  196.6±40.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
  申请人：Incyte Corporation

  公开号：US20180072720A1

  公开（公告）日：2018-03-15

  Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

  揭示了化合物的公式（I），使用这些化合物抑制HPK1活性的方法以及包含这些化合物的药物组合物。这些化合物在治疗、预防或改善与HPK1活性相关的疾病或紊乱方面是有用的，如癌症。
• ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：LES LABORATOIRES SERVIER

  公开号：US20170137385A1

  公开（公告）日：2017-05-18

  A compound of formula (I): wherein the substituents are as defined in the description. Medicinal products containing the same which are useful in treating or preventing pathologies which are the result of activation of the RhoA/ROCK pathway and phosphorylation of the myosin light chain.

  式（I）的化合物：其中取代基如描述中所定义。含有相同化合物的药品，可用于治疗或预防由RhoA/ROCK途径的激活和肌球蛋白轻链的磷酸化所导致的病理。
• PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
  申请人：Incyte Corporation

  公开号：US20180072741A1

  公开（公告）日：2018-03-15

  Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

  揭示了化合物的结构式（I），使用这些化合物抑制HPK1活性的方法以及包含这些化合物的药物组合物。这些化合物可用于治疗、预防或缓解与HPK1活性相关的疾病或疾病，如癌症。
• Pyrazolopyridine compounds and uses thereof
  申请人：Incyte Corporation

  公开号：US10266530B2

  公开（公告）日：2019-04-23

  Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

  本发明公开了式（I）化合物、使用该化合物抑制 HPK1 活性的方法以及包含该化合物的药物组合物。这些化合物可用于治疗、预防或改善与 HPK1 活性相关的疾病或紊乱，如癌症。
• Pyrazolopyrimidine compounds and uses thereof
  申请人：Incyte Corporation

  公开号：US11014929B2

  公开（公告）日：2021-05-25

  Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt thereof. Also provided are methods of using the compounds of Formula (I) for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

  公开的是式 (I) 化合物： 或其药学上可接受的盐。还提供了使用式（I）化合物抑制 HPK1 活性的方法和包含此类化合物的药物组合物。这些化合物可用于治疗、预防或改善与 HPK1 活性相关的疾病或紊乱，如癌症。